Products for Research Use Only

Ethynylcytidine

CAT: 0804-HY-16200-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16200-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer[1][2][3]. Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CAS Number
180300-43-0
Product Name Alternative
ECyD; TAS-106; 3'-C-Ethynylcytidine
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Ethynylcytidine.html
Concentration
10mM
Purity
99.97
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
OC[C@@H]1[C@](O)(C#C)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1
Molecular Formula
C11H13N3O5
Molecular Weight
267.24
Precautions
H302, H315, H319, H335
References & Citations
[1]Shimamoto Y, et al. Antitumor activity and pharmacokinetics of TAS-106, 1- (3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine. Jpn J Cancer Res. 2001 Mar;92 (3) :343-51.|[2]Abdelrahim M, et al. TAS-106: preclinical, clinical and beyond. Oncology. 2013;85 (6) :356-363.|[3]Hammond-Thelin LA, et al. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. Invest New Drugs. 2012;30 (1) :316-326.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Related Products